HNWAG
RUBY

High Net Worth Advisory Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

High Net Worth Advisory Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed -$5K – 741
2021
Q4 		$5K Buy
+500
New +$6.93K ﹤0.01% 613

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

High Net Worth Advisory Group's RUBY Position: Q1 2022 in Review

High Net Worth Advisory Group sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2022, closing a stake of 500 shares — an estimated $5K sold.

High Net Worth Advisory Group first reported a position in RUBY in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 117 funds tracked by Wall St. Rank hold RUBY as of Q1 2022.

  • High Net Worth Advisory Group reported no remaining Rubius Therapeutics, Inc position as of Q1 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 500 Rubius Therapeutics, Inc shares in Q1 2022, an estimated $5K.
  • High Net Worth Advisory Group first reported a position in Rubius Therapeutics, Inc in Q4 2021 and held it in 1 quarter.
  • High Net Worth Advisory Group's Rubius Therapeutics, Inc position peaked at $5K in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2022.

Based on High Net Worth Advisory Group's 13F filing for Q1 2022, filed 13 May 2022.